![](/wp-content/uploads/2021/02/LexiconAnalysis.png)
$599
Thoughts on Sotagliflozin HF Indication after Entresto’s PARAGON Approval
Last week, Novartis received FDA approval for expanding the Entresto label in HF beyond HFrEF (previous FENIX insight). Ahead of Lexicon’s Q4 2020 earnings later in March, FENIX provides a reminder on the recent sequence of events in HF and thoughts on how the new HF labeling for Entresto could apply to Lexicon’s SGLTi, sotagliflozin.